Societe General Downgrades Novartis AG (NVS) to Hold
More News related to NVS
- Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
- Register Your Company Now for the 2009 IR Global Rankings
- Credit Suisse Upgrades Novartis (NVS) to Neutral
- Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
- RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
More News related to Downgrades
- Canaccord Adams Downgrades Freeport-McMoRan (FCX) to Sell, Slashes Price Target
- Jefferies Downgrades Advanced Medical Optics (EYE) to Underperform
- Susquehanna Downgrades Isle of Capri Casinos (ISLE) to Neutral
- Susquehanna Downgrades Boyd Gaming Corporation (BYD) to Neutral
- Susquehanna Downgrades MGM MIRAGE (MGM) to Neutral
Societe General downgrades Novartis AG (NYSE: NVS) from Buy to Hold.
Novartis AG provides healthcare solutions that address the needs of patients and societies worldwide.
Related Categories
DowngradesStocks Mentioned
-1.95Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
